Heart Attack Survivors Can Lower Stroke Risk By Taking Cholesterol-Lowering Drug, Study Says

February 07, 1998

CONTACT:
Brian Henry or Trish Moreis
AHA News Media Relations
Omni Rosen Hotel
(407) 370-6151
NR 98-4849 (StrokeConf/CARE)

ORLANDO, Feb. 7 -- New data reveal that the cholesterol-lowering drug pravastatin (Pravachol) can significantly reduce the risk of a stroke or ministroke in people who have previously suffered a heart attack.

An analysis of the Cholesterol and Recurrent Events (CARE) study found a 32 percent reduction in strokes and a 27 percent reduction in either strokes or transient ischemic attacks (TIAs) -- "miniature" strokes, which can last from few minutes to an hour or more -- among participants treated with the drug as compared to those who received a placebo.

The results were presented here today at the American Heart Association's 23rd International Joint Conference on Stroke and Cerebral Circulation by Jonathan F. Plehn, M.D., associate professor of medicine at Dartmouth Medical School and director of the cardiac ultrasound laboratory at the Dartmouth-Hitchcock Medical Center in Lebanon, N.H.

The vast majority of strokes occur when the vessels providing blood and nutrients to the brain are blocked by cholesterol-laden plaque, which breaks free from the inner lining of the heart's coronary artery. Heart attacks result when coronary arteries are obstructed by atherosclerosis.

"The key point is that if you have a heart attack, you are at high risk of developing a stroke. If you have a stroke, you are at high risk of developing a heart attack," says Plehn. "So it makes sense to be aggressive with a strong drug to lower cholesterol in people who've had a heart attack or stroke because cholesterol reduction should reduce the amount of atherosclerosis in the coronary arteries and in the carotid arteries leading to the brain."

The new study expands upon findings from two recent drug trials. These studies examined whether lowering cholesterol in people who survived a first heart attack reduced the risk of a second attack. Both studies did find a reduced heart attack risk and evidence that lowering cholesterol also lowered a survivor's stroke risk.

Each study used a different drug from a group called HMG-CoA reductase inhibitors: simvastatin (Zocor) in the Scandinavian Simvastatin Survival Study (4S) and pravastatin in CARE. Researchers who designed 4S did not plan to test simvastatin's effectiveness in stroke, but in 1994 they reported a retrospective analysis that showed fewer strokes in patients getting simvastatin.

CARE, however, did include stroke reduction as a secondary part of its investigation. Plehn says that this part of the investigation makes the CARE stroke analysis more acceptable to statisticians. The team's initial paper in 1996 reported a 31 percent reduction in stroke, based on the reports of study investigators.

The new stroke analysis presented at the American Heart Association meeting involved a far-more detailed examination of the CARE data. The records of any patient who might have suffered a stroke were examined by two members of a special committee.

"Strokes are sometimes hard to diagnose," Plehn says. "We looked at hundreds of reported events to verify that they had indeed been strokes and not migraine headaches or something else that might appear to be strokes."

This work revealed that 128 CARE participants (52 taking pravastatin and 76 on placebo) suffered confirmed strokes during the median follow-up period of five years. The data showed a 32 percent lower risk for the drug group. A total of 216 people (92 on pravastatin and 124 on placebo) suffered either a stroke or TIA, a risk reduction of 27 percent for those getting pravastatin.

These findings held up when the team adjusted the results for age, sex, history of hypertension, cigarette smoking, diabetes, and levels of total cholesterol and "bad" LDL and "good" LDL cholesterol.

The study also yielded another tantalizing finding. In the main CARE study, researchers found that people whose "bad cholesterol" readings were below 125 mg/dl did not benefit from taking pravastatin in terms of a reduced heart-attack risk. This "threshold" effect, however, was not found in stroke patients. Study participants with LDLs under 125 had a 25 percent reduction in strokes; those with LDLs between 125 and 150 had a 28 percent lower chance of stroke; and those whose LDL levels were higher than 150 had a 44 percent lower stroke rate.

"The LDL numbers are fairly large in terms of the reduction in stroke, but because there were far fewer strokes than recurrent heart attacks, the power to detect the difference between the active therapy and the placebo was less. So none of the LDL numbers is statistically significant," says Plehn.

Nonetheless, he added, "the data are suggestive that if you have a high LDL cholesterol to start, pravastatin will make a big difference in terms of stroke reduction."

Co-authors are Jean L. Rouleau, M.D., Montreal Heart Institute; Marc A. Pfeffer, M.D., Ph.D., Eugene Braunwald, M.D., and Frank M. Sacks, M.D., Brigham and Women's Hospital, Harvard Medical School; Barry R. Davis, M.D., Ph.D., Lemuel A. Moye, M.D., Ph.D., Linda B. Piller, M.D., M.P.H., and Lara M. Simpson, M.S., University of Texas Health Science Center; Victoria Bernstein, M.D., Vancouver Hospital and Health Sciences Center, University of British Columbia, Vancouver; T. Edward Cuddy, M.D., University of Manitoba Health Sciences Center; and John D. Rutherford, M.D., University of Texas Southwestern Medical Center.
-end-
Media advisory: Dr. Plehn can be reached by calling (603) 650-6154. (Please do not publish telephone numbers.)
-end-


American Heart Association

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.